Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
McKesson
Moodys
Harvard Business School
Express Scripts

Last Updated: May 26, 2022

VAZALORE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Vazalore, and what generic alternatives are available?

Vazalore is a drug marketed by Plx Pharma and is included in one NDA. There are four patents protecting this drug.

This drug has forty-two patent family members in eighteen countries.

The generic ingredient in VAZALORE is aspirin. There are twenty-two drug master file entries for this compound. Additional details are available on the aspirin profile page.

DrugPatentWatch® Generic Entry Outlook for Vazalore

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Summary for VAZALORE
International Patents:42
US Patents:4
Applicants:1
NDAs:1
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in VAZALORE?VAZALORE excipients list
DailyMed Link:VAZALORE at DailyMed
Drug patent expirations by year for VAZALORE

US Patents and Regulatory Information for VAZALORE

VAZALORE is protected by eight US patents.

Patents protecting VAZALORE

Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Methods of treating inflammation with compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT/PREVENTION OF CARDIOVASCULAR DISEASE

Methods of treating inflammation with compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TEMPORARY REDUCTION OF FEVER

Methods of treating inflammation with compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TEMPORARY RELIEF OF MINOR ACHES AND PAINS

pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT/PREVENTION OF CARDIOVASCULAR DISEASE

pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TEMPORARY RELIEF OF MINOR ACHES AND PAINS

pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TEMPORARY REDUCTION OF FEVER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Plx Pharma VAZALORE aspirin CAPSULE;ORAL 203697-002 Feb 26, 2021 OTC Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Plx Pharma VAZALORE aspirin CAPSULE;ORAL 203697-001 Jan 14, 2013 OTC Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Plx Pharma VAZALORE aspirin CAPSULE;ORAL 203697-001 Jan 14, 2013 OTC Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Plx Pharma VAZALORE aspirin CAPSULE;ORAL 203697-001 Jan 14, 2013 OTC Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VAZALORE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Plx Pharma VAZALORE aspirin CAPSULE;ORAL 203697-001 Jan 14, 2013 See Plans and Pricing See Plans and Pricing
Plx Pharma VAZALORE aspirin CAPSULE;ORAL 203697-001 Jan 14, 2013 See Plans and Pricing See Plans and Pricing
Plx Pharma VAZALORE aspirin CAPSULE;ORAL 203697-001 Jan 14, 2013 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for VAZALORE

See the table below for patents covering VAZALORE around the world.

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 02085414 See Plans and Pricing
Slovenia 1343529 See Plans and Pricing
Brazil 0116380 Método e composições que empregam formulaçoes de óleos de lecitina e fármacos antiinflamatórios não-esteróides (nsaids) para proteger o trato gastrointestinal e proporcionar maior atividade terapêutica See Plans and Pricing
Japan 4958381 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VAZALORE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0984957 2012/048 Ireland See Plans and Pricing PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812
0984957 122012000017 Germany See Plans and Pricing PRODUCT NAME: ASPIRIN UND ESOMEPRAZOL - MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 81047.00.00 20110930 FIRST REGISTRATION: PORTUGAL 5402359 5402367 5402375 20110812
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Medtronic
Mallinckrodt
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.